Group structure
3 companies in 2 countries
Canada1
United States1
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine of every company in the group, current ones first.
9 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| APONVIE32mg/4.4ml (7.2mg/ml) · Emulsion | Aprepitant | United States | Marketed | 2022 |
| CINVANTI130mg/18ml (7.2mg/ml) · Emulsion | Aprepitant | United States | Marketed | 2017 |
| SUSTOL10mg/0.4ml (10mg/0.4ml) · Injectable | Granisetron | United States | Marketed | 2016 |
| ZYNRELEF KIT200mg/7ml (29.25mg/ml); 6mg/7ml (0.88mg/ml) | 300mg/10.5ml (29.25mg/ml); 9mg/10.5ml (0.88mg/ml) | 400mg/14ml (29.25mg/ml); 12mg/14ml (0.88mg/ml) | 60mg/2.3ml (29.25mg/ml); 1.8mg/2.3ml (0.88mg/ml) · Solution, extended release | Bupivacaine, Meloxicam | United States | Marketed | 2021 |
| ZYNRELEF200 mg / 7 ml + 6 mg / 7 ml · Solution (Extended-Release) | Bupivacaine, Meloxicam | Canada | Cancelled | |
| Zynrelef | Bupivacaine, Meloxicam | EU (EMA) | Withdrawn | 2020 |
| ZYNRELEF400 mg / 14 ml + 12 mg / 14 ml · Solution (Extended-Release) | Bupivacaine, Meloxicam | Canada | Cancelled | |
| ZYNRELEF60 mg / 2.3 ml + 1.8 mg / 2.3 ml · Solution (Extended-Release) | Bupivacaine, Meloxicam | Canada | Cancelled | |
| ZYNRELEF300 mg / 10.5 ml + 9 mg / 10.5 ml · Solution (Extended-Release) | Bupivacaine, Meloxicam | Canada | Cancelled |